Clinical Outcome of the ACCORD 12/0405 PRODIGE 2 Randomized Trial in Rectal Cancer
Jean‐Pierre Gérard(Centre Antoine Lacassagne), Thierry Conroy(Inserm), Y. Bécouarn, Christophe Hennequin(American Society of Clinical Oncology), Olivier Dupuis(Centre National de la Recherche Scientifique), Jean-François Berdah(American Society of Clinical Oncology), D. Azria(Inserm), Laurent Bedenne(CHU Dijon Bourgogne), V. Vendrely(Centre Hospitalier Universitaire de Bordeaux), Éric François(Centre Antoine Lacassagne), Isabelle Martel‐Lafay(Centre Léon Bérard), Pierre-Luc Etienne, Laurent Mineur(Institut Sainte Catherine), Olivier Bouché(CHU Dijon Bourgogne), Béata Juzyna(Université Paris Cité), Bernard Denis(American Society of Clinical Oncology), Jean‐François Seitz(Aix-Marseille Université), Marc-André Mahé(American Society of Clinical Oncology), Gérard Lledo(American Society of Clinical Oncology), S. Gourgou-Bourgade(CEA Valduc), Guy de La Roche(American Society of Clinical Oncology), X. Mirabel(American Society of Clinical Oncology)
Cited by 431
Related Papers
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
|New England Journal of Medicine|2018|2.8k
Chemotherapy with Preoperative Radiotherapy in Rectal Cancer
|New England Journal of Medicine|2006|2.7k
Perioperative Chemotherapy Compared With Surgery Alone for Resectable Gastroesophageal Adenocarcinoma: An FNCLCC and FFCD Multicenter Phase III Trial
|Journal of Clinical Oncology|2011|2.1k
Preoperative Radiotherapy With or Without Concurrent Fluorouracil and Leucovorin in T3-4 Rectal Cancers: Results of FFCD 9203
|Journal of Clinical Oncology|2006|1.7k
Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2015|1.3k